quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:07:41·34d
SECFiling
Milestone Pharmaceuticals Inc. logo

SEC Form 10-K filed by Milestone Pharmaceuticals Inc.

MIST· Milestone Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • MIST
    Milestone Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 10UpdateRaymond James$6.00
  • Dec 15UpdateTD Cowen$8.00
  • Sep 11UpdateWells Fargo$4.00
  • Jun 5UpdateH.C. Wainwright$5.00
  • Aug 22UpdateRodman & Renshaw$9.00
  • Jun 20UpdateJefferies$4.00

Related

  • INSIDER3d
    SEC Form 4 filed by Oliveto Joseph
  • ANALYST13d
    Raymond James initiated coverage on Milestone Pharmaceuticals with a new price target
  • PR13d
    Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
  • PR16d
    Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
  • PR23d
    Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
  • INSIDER31d
    SEC Form 3 filed by new insider Sandoval David I.
  • SEC34d
    Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR34d
    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022